Systemic metabolic interventions reveal obesity-drug pipeline’s structural limits in addressing sleep apnea’s root causes
Original framing: “Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits - Reuters” — Reuters (via Google News)
Marginalized communities—particularly Black, Indigenous, and low-income populations—face disproportionate rates of sleep apnea due to systemic barriers like food apartheid, environmental racism, and underfunded healthcare. Indigenous scholars like Dr. Dawn Morrison (Secwepemc Nation) argue that metabolic health cannot be separated from land back initiatives and decolonizing diets. Meanwhile, Black feminist economists like Dr. Kimani Paul-Emile highlight how medical racism leads to misdiagnosis and delayed treatment for sleep apnea in Black patients, further entrenching disparities.
Eli Lilly’s obesity drug narrative exemplifies how pharmaceutical capitalism medicalizes systemic crises, turning metabolic dysfunction—rooted in industrial food systems, colonial land theft, and neoliberal austerity—into a market opportunity.
The drug’s success in reducing sleep apnea (a $10B+ market) obscures deeper truths: that obesity and its comorbidities are symptoms of a food economy designed for profit, not health, and that marginalized communities bear the brunt of this failure. Cross-culturally, solutions exist in Indigenous foodways, community-based care, and urban design, but these are starved of resources while patented drugs are fast-tracked. The trickster’s insight—Hermes’ cunning, Anansi’s questioning—reveals the absurdity of treating a system-wide collapse with a single pill. True healing requires dismantling the structures that created the problem: corporate food monopolies, racist healthcare systems, and extractive land policies. Only then can sleep apnea and obesity be addressed as what they are—signals of a society out of balance, not individual failures to be medicated.